These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 19498000)

  • 21. Clinical implication of genome-wide profiling in diffuse large B-cell lymphoma and other subtypes of B-cell lymphoma.
    Iqbal J; Joshi S; Patel KN; Javed SI; Kucuk C; Aabida A; d'Amore F; Fu K
    Indian J Cancer; 2007; 44(2):72-86. PubMed ID: 17938484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.
    Cani AK; Soliman M; Hovelson DH; Liu CJ; McDaniel AS; Haller MJ; Bratley JV; Rahrig SE; Li Q; Briceño CA; Tomlins SA; Rao RC
    Mod Pathol; 2016 Jul; 29(7):685-97. PubMed ID: 27102345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of differentially expressed proteins in chemotherapy-sensitive and chemotherapy-resistant diffuse large B cell lymphoma by proteomic methods.
    Liu Y; Zeng L; Zhang S; Zeng S; Huang J; Tang Y; Zhong M
    Med Oncol; 2013 Jun; 30(2):528. PubMed ID: 23504336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in human B cells.
    van Keimpema M; Grüneberg LJ; Schilder-Tol EJ; Oud ME; Beuling EA; Hensbergen PJ; de Jong J; Pals ST; Spaargaren M
    Haematologica; 2017 Mar; 102(3):573-583. PubMed ID: 27909217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrative genomic analysis of temozolomide resistance in diffuse large B-cell lymphoma.
    Leshchenko VV; Kuo PY; Jiang Z; Thirukonda VK; Parekh S
    Clin Cancer Res; 2014 Jan; 20(2):382-92. PubMed ID: 24178621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T-cell/histiocyte-rich large B-cell lymphoma is a disseminated aggressive neoplasm: differential diagnosis from Hodgkin's lymphoma.
    Fraga M; Sánchez-Verde L; Forteza J; García-Rivero A; Piris MA
    Histopathology; 2002 Sep; 41(3):216-29. PubMed ID: 12207783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
    Davies A; Cummin TE; Barrans S; Maishman T; Mamot C; Novak U; Caddy J; Stanton L; Kazmi-Stokes S; McMillan A; Fields P; Pocock C; Collins GP; Stephens R; Cucco F; Clipson A; Sha C; Tooze R; Care MA; Griffiths G; Du MQ; Westhead DR; Burton C; Johnson PWM
    Lancet Oncol; 2019 May; 20(5):649-662. PubMed ID: 30948276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas.
    Krenacs L; Himmelmann AW; Quintanilla-Martinez L; Fest T; Riva A; Wellmann A; Bagdi E; Kehrl JH; Jaffe ES; Raffeld M
    Blood; 1998 Aug; 92(4):1308-16. PubMed ID: 9694719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines.
    Culpin RE; Proctor SJ; Angus B; Crosier S; Anderson JJ; Mainou-Fowler T
    Int J Oncol; 2010 Aug; 37(2):367-76. PubMed ID: 20596664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T-cell/histiocyte-rich large B-cell lymphoma: a heterogeneous entity with derivation from germinal center B cells.
    Lim MS; Beaty M; Sorbara L; Cheng RZ; Pittaluga S; Raffeld M; Jaffe ES
    Am J Surg Pathol; 2002 Nov; 26(11):1458-66. PubMed ID: 12409722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteomic Landscape of Extracellular Vesicles for Diffuse Large B-Cell Lymphoma Subtyping.
    Carvalho AS; Baeta H; Henriques AFA; Ejtehadifar M; Tranfield EM; Sousa AL; Farinho A; Silva BC; Cabeçadas J; Gameiro P; Silva MGD; Beck HC; Matthiesen R
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
    Rosenwald A; Wright G; Chan WC; Connors JM; Campo E; Fisher RI; Gascoyne RD; Muller-Hermelink HK; Smeland EB; Giltnane JM; Hurt EM; Zhao H; Averett L; Yang L; Wilson WH; Jaffe ES; Simon R; Klausner RD; Powell J; Duffey PL; Longo DL; Greiner TC; Weisenburger DD; Sanger WG; Dave BJ; Lynch JC; Vose J; Armitage JO; Montserrat E; López-Guillermo A; Grogan TM; Miller TP; LeBlanc M; Ott G; Kvaloy S; Delabie J; Holte H; Krajci P; Stokke T; Staudt LM;
    N Engl J Med; 2002 Jun; 346(25):1937-47. PubMed ID: 12075054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection.
    Arcaini L; Rossi D; Lucioni M; Nicola M; Bruscaggin A; Fiaccadori V; Riboni R; Ramponi A; Ferretti VV; Cresta S; Casaluci GM; Bonfichi M; Gotti M; Merli M; Maffi A; Arra M; Varettoni M; Rattotti S; Morello L; Guerrera ML; Sciarra R; Gaidano G; Cazzola M; Paulli M
    Haematologica; 2015 Feb; 100(2):246-52. PubMed ID: 25381127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses.
    Broséus J; Chen G; Hergalant S; Ramstein G; Mounier N; Guéant JL; Feugier P; Gisselbrecht C; Thieblemont C; Houlgatte R
    Oncotarget; 2016 Dec; 7(51):83987-84002. PubMed ID: 27276707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteomic profiling for cancer progression: Differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines.
    Hayashi E; Kuramitsu Y; Okada F; Fujimoto M; Zhang X; Kobayashi M; Iizuka N; Ueyama Y; Nakamura K
    Proteomics; 2005 Mar; 5(4):1024-32. PubMed ID: 15712240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exosomes and extracellular vesicles as liquid biopsy biomarkers in diffuse large B-cell lymphoma: Current state of the art and unmet clinical needs.
    Ofori K; Bhagat G; Rai AJ
    Br J Clin Pharmacol; 2021 Feb; 87(2):284-294. PubMed ID: 33080045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene selection and cancer type classification of diffuse large-B-cell lymphoma using a bivariate mixture model for two-species data.
    Su Y; Nielsen D; Zhu L; Richards K; Suter S; Breen M; Motsinger-Reif A; Osborne J
    Hum Genomics; 2013 Jan; 7(1):2. PubMed ID: 23289441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas.
    Testo N; Olson LC; Subramaniyam S; Hanson T; Magro CM
    Am J Dermatopathol; 2016 Oct; 38(10):769-74. PubMed ID: 27391453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma.
    Robertus JL; Harms G; Blokzijl T; Booman M; de Jong D; van Imhoff G; Rosati S; Schuuring E; Kluin P; van den Berg A
    Mod Pathol; 2009 Apr; 22(4):547-55. PubMed ID: 19287466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene expression analysis in aggressive NHL.
    Chan WC; Huang JZ
    Ann Hematol; 2001; 80 Suppl 3():B38-41. PubMed ID: 11757704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.